|
|
|
Volumn 23, Issue 3, 1996, Pages 379-389
|
|
Adjuvant and neoadjuvant therapy for gastric cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
DOXORUBICIN;
FLUOROURACIL;
ADJUVANT THERAPY;
ADULT;
ADVANCED CANCER;
CANCER RECURRENCE;
CANCER RISK;
CANCER STAGING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG MEGADOSE;
HIGH RISK POPULATION;
HUMAN;
HYPOTHESIS;
MAJOR CLINICAL STUDY;
PHASE 2 CLINICAL TRIAL;
POSTOPERATIVE PERIOD;
PRIORITY JOURNAL;
RECURRENCE RISK;
REVIEW;
STOMACH CANCER;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL PROTOCOLS;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
COMBINED MODALITY THERAPY;
EUROPE;
GASTRECTOMY;
HUMANS;
IMMUNOTHERAPY;
LIVER NEOPLASMS;
NEOPLASM RECURRENCE, LOCAL;
PERITONEAL NEOPLASMS;
RADIOTHERAPY, ADJUVANT;
STOMACH NEOPLASMS;
UNITED STATES;
|
|
EID: 0029893467
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (105)
|
|
References (0)
|
